Paroxetine in patients with irritable bowel syndrome

A pilot open-label study

Prakash S. Masand, Sanjay Gupta, Thomas L. Schwartz, Subhdeep Virk, Kari Lockwood, Ahmad Hameed, Monica King, David S. Kaplan

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Irritable bowel syndrome (IBS) is a common disorder and is the largest diagnostic cohort seen by gastroenterologists. There is a bidirectional comorbidity of IBS and psychiatric illness. Ours is the first study to examine the effect of any selective serotonin reuptake inhibitor in subjects with IBS. Method: Twenty subjects with Rome I criteria - diagnosed IBS were treated with 20 to 40 mg of paroxetine for 12 weeks. We utilized a computer-administered patient daily questionnaire taken by patients over the telephone using an interactive voice response system. Results: Sixty-five percent of patients (13/20) reported a reduction in abdominal pain, and 55% (11/20) reported a reduction in pain frequency (total or mean number of days per week in which the patient had the symptom decreased by a 50%). Constipation and diarrhea were reduced in 69% and 57% of patients (9/13 and 8/14), respectively. Similarly, a clinically significant reduction in the symptoms of feeling of incomplete emptying (53% [9/17]) and bloating/abdominal distension (55% [11/20]) was apparent at study conclusion compared with baseline. On the Clinical Global Impressions scale at week 12, 47% (8/17) of the patients were much or very much improved. Conclusion: In our pilot open-label study, paroxetine was very effective in alleviating the abdominal pain and associated symptoms of IBS. These results warrant further examination in a placebo-controlled study.

Original languageEnglish (US)
Pages (from-to)12-16
Number of pages5
JournalPrimary Care Companion to the Journal of Clinical Psychiatry
Volume4
Issue number1
StatePublished - Dec 1 2002

Fingerprint

Paroxetine
Irritable Bowel Syndrome
Abdominal Pain
Serotonin Uptake Inhibitors
Constipation
Telephone
Psychiatry
Comorbidity
Diarrhea
Emotions
Placebos
Pain

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

Masand, P. S., Gupta, S., Schwartz, T. L., Virk, S., Lockwood, K., Hameed, A., ... Kaplan, D. S. (2002). Paroxetine in patients with irritable bowel syndrome: A pilot open-label study. Primary Care Companion to the Journal of Clinical Psychiatry, 4(1), 12-16.
Masand, Prakash S. ; Gupta, Sanjay ; Schwartz, Thomas L. ; Virk, Subhdeep ; Lockwood, Kari ; Hameed, Ahmad ; King, Monica ; Kaplan, David S. / Paroxetine in patients with irritable bowel syndrome : A pilot open-label study. In: Primary Care Companion to the Journal of Clinical Psychiatry. 2002 ; Vol. 4, No. 1. pp. 12-16.
@article{6df16732fbb64a9cbdab613de40d7468,
title = "Paroxetine in patients with irritable bowel syndrome: A pilot open-label study",
abstract = "Background: Irritable bowel syndrome (IBS) is a common disorder and is the largest diagnostic cohort seen by gastroenterologists. There is a bidirectional comorbidity of IBS and psychiatric illness. Ours is the first study to examine the effect of any selective serotonin reuptake inhibitor in subjects with IBS. Method: Twenty subjects with Rome I criteria - diagnosed IBS were treated with 20 to 40 mg of paroxetine for 12 weeks. We utilized a computer-administered patient daily questionnaire taken by patients over the telephone using an interactive voice response system. Results: Sixty-five percent of patients (13/20) reported a reduction in abdominal pain, and 55{\%} (11/20) reported a reduction in pain frequency (total or mean number of days per week in which the patient had the symptom decreased by a 50{\%}). Constipation and diarrhea were reduced in 69{\%} and 57{\%} of patients (9/13 and 8/14), respectively. Similarly, a clinically significant reduction in the symptoms of feeling of incomplete emptying (53{\%} [9/17]) and bloating/abdominal distension (55{\%} [11/20]) was apparent at study conclusion compared with baseline. On the Clinical Global Impressions scale at week 12, 47{\%} (8/17) of the patients were much or very much improved. Conclusion: In our pilot open-label study, paroxetine was very effective in alleviating the abdominal pain and associated symptoms of IBS. These results warrant further examination in a placebo-controlled study.",
author = "Masand, {Prakash S.} and Sanjay Gupta and Schwartz, {Thomas L.} and Subhdeep Virk and Kari Lockwood and Ahmad Hameed and Monica King and Kaplan, {David S.}",
year = "2002",
month = "12",
day = "1",
language = "English (US)",
volume = "4",
pages = "12--16",
journal = "The primary care companion for CNS disorders",
issn = "1523-5998",
publisher = "Physicians Postgraduate Press Inc.",
number = "1",

}

Masand, PS, Gupta, S, Schwartz, TL, Virk, S, Lockwood, K, Hameed, A, King, M & Kaplan, DS 2002, 'Paroxetine in patients with irritable bowel syndrome: A pilot open-label study', Primary Care Companion to the Journal of Clinical Psychiatry, vol. 4, no. 1, pp. 12-16.

Paroxetine in patients with irritable bowel syndrome : A pilot open-label study. / Masand, Prakash S.; Gupta, Sanjay; Schwartz, Thomas L.; Virk, Subhdeep; Lockwood, Kari; Hameed, Ahmad; King, Monica; Kaplan, David S.

In: Primary Care Companion to the Journal of Clinical Psychiatry, Vol. 4, No. 1, 01.12.2002, p. 12-16.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Paroxetine in patients with irritable bowel syndrome

T2 - A pilot open-label study

AU - Masand, Prakash S.

AU - Gupta, Sanjay

AU - Schwartz, Thomas L.

AU - Virk, Subhdeep

AU - Lockwood, Kari

AU - Hameed, Ahmad

AU - King, Monica

AU - Kaplan, David S.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Background: Irritable bowel syndrome (IBS) is a common disorder and is the largest diagnostic cohort seen by gastroenterologists. There is a bidirectional comorbidity of IBS and psychiatric illness. Ours is the first study to examine the effect of any selective serotonin reuptake inhibitor in subjects with IBS. Method: Twenty subjects with Rome I criteria - diagnosed IBS were treated with 20 to 40 mg of paroxetine for 12 weeks. We utilized a computer-administered patient daily questionnaire taken by patients over the telephone using an interactive voice response system. Results: Sixty-five percent of patients (13/20) reported a reduction in abdominal pain, and 55% (11/20) reported a reduction in pain frequency (total or mean number of days per week in which the patient had the symptom decreased by a 50%). Constipation and diarrhea were reduced in 69% and 57% of patients (9/13 and 8/14), respectively. Similarly, a clinically significant reduction in the symptoms of feeling of incomplete emptying (53% [9/17]) and bloating/abdominal distension (55% [11/20]) was apparent at study conclusion compared with baseline. On the Clinical Global Impressions scale at week 12, 47% (8/17) of the patients were much or very much improved. Conclusion: In our pilot open-label study, paroxetine was very effective in alleviating the abdominal pain and associated symptoms of IBS. These results warrant further examination in a placebo-controlled study.

AB - Background: Irritable bowel syndrome (IBS) is a common disorder and is the largest diagnostic cohort seen by gastroenterologists. There is a bidirectional comorbidity of IBS and psychiatric illness. Ours is the first study to examine the effect of any selective serotonin reuptake inhibitor in subjects with IBS. Method: Twenty subjects with Rome I criteria - diagnosed IBS were treated with 20 to 40 mg of paroxetine for 12 weeks. We utilized a computer-administered patient daily questionnaire taken by patients over the telephone using an interactive voice response system. Results: Sixty-five percent of patients (13/20) reported a reduction in abdominal pain, and 55% (11/20) reported a reduction in pain frequency (total or mean number of days per week in which the patient had the symptom decreased by a 50%). Constipation and diarrhea were reduced in 69% and 57% of patients (9/13 and 8/14), respectively. Similarly, a clinically significant reduction in the symptoms of feeling of incomplete emptying (53% [9/17]) and bloating/abdominal distension (55% [11/20]) was apparent at study conclusion compared with baseline. On the Clinical Global Impressions scale at week 12, 47% (8/17) of the patients were much or very much improved. Conclusion: In our pilot open-label study, paroxetine was very effective in alleviating the abdominal pain and associated symptoms of IBS. These results warrant further examination in a placebo-controlled study.

UR - http://www.scopus.com/inward/record.url?scp=4143052298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143052298&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 12

EP - 16

JO - The primary care companion for CNS disorders

JF - The primary care companion for CNS disorders

SN - 1523-5998

IS - 1

ER -